دورية أكاديمية
Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas.
| العنوان: | Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas. |
|---|---|
| المؤلفون: | Winder AA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. alecwinder81@gmail.com., Boyer Z; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia., Ch'ng S; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Mater Hospital, Sydney, NSW, Australia., Stretch JR; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Mater Hospital, Sydney, NSW, Australia., Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Mater Hospital, Sydney, NSW, Australia., Shannon KF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Mater Hospital, Sydney, NSW, Australia., Pennington TE; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia.; Mater Hospital, Sydney, NSW, Australia., Nieweg OE; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Varey AHR; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia., Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal Prince Alfred Hospital, Sydney, NSW, Australia., Cust AE; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; The Daffodil Centre, University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW, Australia., Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia., Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty Medicine and Health, The University of Sydney, Sydney, NSW, Australia.; Royal North Shore Hospital, Sydney, NSW, Australia.; Mater Hospital, Sydney, NSW, Australia., Smith AL; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.; The Daffodil Centre, University of Sydney, A Joint Venture with Cancer Council NSW, Sydney, NSW, Australia. |
| المصدر: | Annals of surgical oncology [Ann Surg Oncol] 2024 Aug; Vol. 31 (8), pp. 5331-5339. Date of Electronic Publication: 2024 May 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2005- : New York, NY : Springer Original Publication: New York, NY : Raven Press, c1994- |
| مواضيع طبية MeSH: | Melanoma*/pathology , Melanoma*/surgery , Sentinel Lymph Node Biopsy* , Nomograms* , Sentinel Lymph Node*/pathology , Sentinel Lymph Node*/surgery , Skin Neoplasms*/pathology , Skin Neoplasms*/surgery, Humans ; Female ; Male ; Middle Aged ; Risk Assessment ; Aged ; Follow-Up Studies ; Prognosis ; Adult ; Lymphatic Metastasis ; Neoplasm Staging ; Retrospective Studies ; Aged, 80 and over |
| مستخلص: | Background: Predicting which patients with American Joint Committee on Cancer (AJCC) T1-T2 melanomas will have a positive sentinel lymph node (SLN) is challenging. Melanoma Institute Australia (MIA) developed an internationally validated SLN metastatic risk calculator. This study evaluated the nomogram's impact on T1-T2 melanoma patient management at MIA. Methods: SLN biopsy (SLNB) rates were compared for the pre- and post-nomogram periods of 1 July 2018-30 June 2019 and 1 August 2020-31 July 2021, respectively. Results: Overall, 850 patients were identified (pre-nomogram, 383; post-nomogram, 467). SLNB was performed in 29.0% of patients in the pre-nomogram group and 34.5% in the post-nomogram group (p = 0.091). The overall positivity rate was 16.2% in the pre-nomogram group and 14.9% in the post-nomogram group (p = 0.223). SLNB was performed less frequently in T1a melanoma patients in the pre-nomogram group (1.1%, n = 2/177) than in the post-nomogram group (8.6%, n = 17/198) [p ≤ 0.001]. This increase was particularly for melanomas with a risk score ≥ 5%, with an SLN positivity rate of 11.8% in the post-nomogram group (p = 0.004) compared with zero. For T1b melanomas with a risk score of > 10%, the SLNB rate was 40.0% (8/20) pre-nomogram and 75.0% (12/16) post-nomogram (p = 0.049). Conclusions: In this specialized center, the SLN risk calculator appears to influence practice for melanomas previously considered low risk for metastasis, with increased use of SLNB for T1a and higher-risk T1b melanomas. Further evaluation is required across broader practice settings. Melanoma management guidelines could be updated to incorporate the availability of nomograms to better select patients for SLNB than previous criteria. (© 2024. The Author(s).) |
| References: | Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609. (PMID: 10.1056/NEJMoa1310460245211064058881) Cancer council Australia 2021. Clinical guidelines Melanoma. Available at: https://wiki.cancer.org.au/australia/Clinical_question:When_is_a_sentinel_node_biopsy_indicated%3F . Accessed Sep 2021. Gershenwald JE, Scolyer RA. Melanoma staging: American joint committee on cancer (AJCC) 8 th edition Beyond. Ann Surg Oncol. 2018;25(8):2105–10. (PMID: 10.1245/s10434-018-6513-729850954) NCCN Guidelines Version 2.2022 Melanoma: Cutaneous, ME-2A. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf . Accessed Jan 2022. Warycha MA, Zakrzewski J, Ni Q, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma. Cancer. 2009;115(4):869–79. (PMID: 10.1002/cncr.2404419117354) Moody JA, Ali RF, Carbone AC, Singh S, Hardwicke JT. Complications of sentinel lymph node biopsy for melanoma: a systematic review of the literature. Eur J Surg Oncol. 2017;43(2):270–7. (PMID: 10.1016/j.ejso.2016.06.40727423448) Ipenburg NA, Thompson JF, Uren RF, Chung D, Nieweg OE. Focused ultrasound surveillance of lymph nodes following lymphoscintigraphy without sentinel node biopsy: A useful and safe strategy in elderly or frail melanoma patients. Ann Surg Oncol. 2019;26(9):2855–63. (PMID: 10.1245/s10434-019-07505-6312405886682569) Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12(4):282–8. (PMID: 10.1245/ASO.2005.05.01615827679) Lo SN, Ma J, Scolyer RA, Haydu LE, et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma institute Australia nomogram. J Clin Oncol. 2020;38(24):2719–27. (PMID: 10.1200/JCO.19.02362325307617430218) Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. (PMID: 10.1016/0021-9681(87)90171-83558716) Shannon AB, Sharon CE, Straker RJ 3rd, et al. Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: a multicenter cohort study. J Am Acad Dermatol. 2023;88(1):52–9. (PMID: 10.1016/j.jaad.2022.09.04036184008) Maurichi A, Miceli R, Eriksson H, et al. Factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: development and external validation of a predictive nomogram. J Clin Oncol. 2020;38(14):1591–601. (PMID: 10.1200/JCO.19.01902321678627213590) Farberg AS, Marson JW, Glazer A, et al. Expert consensus on the use of prognostic gene expression profiling tests for the management of cutaneous melanoma: consensus from the skin cancer prevention working group. Dermatol Ther (Heidelb). 2022;12:807–23. (PMID: 10.1007/s13555-022-00709-x35353350) |
| معلومات مُعتمدة: | 1093017 National Health and Medical Research Council; 2008454 National Health and Medical Research Council; 2018514 National Health and Medical Research Council; 1135285 Melanoma Centre of Research Excellence |
| تواريخ الأحداث: | Date Created: 20240527 Date Completed: 20240712 Latest Revision: 20240716 |
| رمز التحديث: | 20240716 |
| مُعرف محوري في PubMed: | PMC11236927 |
| DOI: | 10.1245/s10434-024-15456-w |
| PMID: | 38802717 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1534-4681 |
|---|---|
| DOI: | 10.1245/s10434-024-15456-w |